Safety profile of sparfloxacin, a new fluoroquinolone antibiotic

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 148-159

  Lipsky, Benjamin A ^a,d   Dorr, Mary Beth ^b   Magner, D J ^b,c   Talbot, George H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SANOFI   (France)

^c Astra Pharmaceuticals   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Antibiotics; Fluoroquinolones; Phototoxicity; Safety; Sparfloxacin

Indexed keywords

ANTIINFECTIVE AGENT; CEFACLOR; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; OFLOXACIN; QUINOLONE; SPARFLOXACIN;

ADOLESCENT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0033009544     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88275-2     Document Type: Article

References (32)

1. 1. von Rosenstiel N, Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs. 1994;47:872-901.
2. 2. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am. 1995;9:715-730.
3. 3. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis. 1988;10(Suppl 1):S258-S261.
4. 4. Schentag JJ, Nix DE, Wise R. Pharmacokinetics and tissue penetration of quinolones. In: Siporin C, Heifetz CL, Domagala JM, eds. The New Generation of Quinolones. New York: Marcel Dekker; 1990:189-222.
5. 5. Montay G, Bruno R, Vergniol J, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol. 1994;34:1071-1076.
6. 6. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: A review. J Antimicrob Chemother. 1996;37(Suppl A):27-39.
7. 7. Davey P, Parker S. Cost effectiveness of once-daily oral antimicrobial therapy. J Clin Pharmacol. 1992;32:706-710.
8. 8. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989;2:378-424.
9. 9. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993;31:505-522.
10. 10. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother. 1996;37(Suppl A):57-63.
11. 11. Donowitz GR, Brandon ML, Salisbury JP, et al. Sparfloxacin versus cefaclor in the treatment of community-acquired pneumonia: A randomised, double-masked, comparative, multicenter study. Clin Ther. 1997;19:936-953.
12. 12. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin versus ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest. 1998;114:120-130.
13. 13. Garrison N, Spector S, Buffinton D, et al. Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture. Ann Allergy Asthma Immunol. In press.
14. 14. Henry D, Stein W, Bensch G, et al. Sparfloxacin versus erythromycin in the treatment of community-acquired pneumonia. Am J Med. In press.
15. 15. Henry DC, Moller DJ, Adelglass J, et al. Treatment of acute bacterial maxillary sinusitis with sparfloxacin versus clarithromycin. Clin Ther. In press.
16. 16. Lipsky BA, Dorr MB, Magner DJ, Talbot GH. Safety profile of sparfloxacin in North American phase III clinical trials. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, Louisiana; 1996.
17. 17. Peatman JG, ed. Introduction to Applied Statistics. New York: Harper & Row; 1963:245,272,273.
18. 18. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41:361-372.
19. 19. Wijnands WJA, Vree TB, van Herwaarden CLA. Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol. 1985;20:583-588.
20. 20. Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22:677-683.
21. 21. Sarkar M, Polk RE, Guzelian PS, et al. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother. 1990;34:594-599.
22. 22. Fuhr U, Wolff T, Harder S, et al. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos. 1990;18:1005-1010.
23. 23. Okimoto N, Niki Y, Sumi M, et al. Effect of sparfloxacin on serum concentration of theophylline. Chemotherapy (Tokyo). 1991;39(Suppl 4):158-160.
24. 24. Zagam® [package insert]. Rhône-Poulenc Rorer Research and Development; Collegeville, Pennsylvania; 1997.
25. 25. Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother. 1997;41:1668-1672.
26. 26. Shimada J, Saito A, Shiba K, et al. Pharmacokinetics and clinical studies on sparfloxacin. Chemotherapy (Tokyo). 1991;39(Suppl 4):234-244.
27. 27. Johnson RD, Dorr MB, Talbot GH, et al. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20:1149-1158.
28. 28. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994;33:685-706.
29. 29. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother. 1996;37(Suppl A):145-160.
30. 30. Thomas SH. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev. 1994;13:77-102.
31. 31. Jaillon P, Morganroth J, Brumpt I, Talbot G, and the Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37(Suppl A):161-167.
32. 32. Martin SJ, Meyer JM, Chuck SK, et al. Levofloxacin and sparfloxacin: New quinolone antibiotics. Ann Pharmacother. 1998;32:320-336.